02585nam 2200541Ia 450 991082248760332120230801230457.090-6299-859-3(CKB)2670000000343084(EBL)1153134(OCoLC)831118671(SSID)ssj0000921070(PQKBManifestationID)11484062(PQKBTitleCode)TC0000921070(PQKBWorkID)10940492(PQKB)10453115(MiAaPQ)EBC1153134(Au-PeEL)EBL1153134(CaPaEBR)ebr10674877(EXLCZ)99267000000034308420130408d2012 uy 0engur|n|---|||||txtccrVascular considerations in glaucoma[electronic resource] current perspectives /edited by Alon HarrisAmsterdam, Netherlands Kugler20121 online resource (126 p.)Description based upon print version of record.90-6299-235-8 Includes bibliographical references.ABOUT THE AUTHORS; 1. BACKGROUND - THE EMERGENCE OF THEVASCULAR DYSREGULATION THEORY; 2. CLINICAL MEASUREMENT OF OCULAR BLOODFLOW; 3. AUTOREGULATION; 4. VASCULAR RISK FACTORS; 5. DIURNAL VARIATIONS OF INTRAOCULARPRESSURE, BLOOD PRESSURE AND PERFUSIONPRESSURE; 6 THE RELATIONSHIP BETWEEN BLOOD FLOWAND STRUCTURE; 7. OCULAR BLOOD FLOW AND VISUAL FUNCTION; 8. CEREBROSPINAL FLUID PRESSURE ANDGLAUCOMA; 9. TOPICAL MEDICATIONS AND OCULAR BLOODFLOWPrefaceOpen angle glaucoma (OAG) is one of the leading causes of impaired vision worldwide. The pathogenesis of glaucomatous optic neuropathy remains poorly understood, and several pathogenic mechanisms are proposed to coexist. As the world population ages, OAG will become more prevalent and advances in the diagnosis and treatment of glaucomatous optic neuropathy are important to protect and improve the quality of life of our aging population.Treatment of OAG has been directed at lowering intraocular pressure (IOP) which is the only current therapeutic strategy available to patients with glaucGlaucomaRetinaBlood-vesselsGlaucoma.RetinaBlood-vessels.617.7617.74100223Harris Alon1643019MiAaPQMiAaPQMiAaPQBOOK9910822487603321Vascular considerations in glaucoma4040676UNINA